Evidence map›Paper›PMID 40321251›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Transcriptome-wide Mendelian randomisation exploring dynamic CD4+ T cell gene expression in colorectal cancer development.

Benedita Deslandes, Xueyan Wu, Matthew A Lee, Lucy J Goudswaard, Gareth W Jones, Andrea Gsur, Annika Lindblom, Shuji Ogino, Veronika Vymetalkova, Alicja Wolk and 13 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Benedita DeslandesMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.ORCID 0009-0000-2738-4794
Xueyan WuDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Matthew A LeeNutrition and Metabolism Branch, International Agency for Research on Cancer, WHO, Lyon, France.ORCID 0000-0001-6262-3447
Lucy J GoudswaardMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.ORCID 0000-0003-1481-6871
Gareth W JonesSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID 0000-0002-0125-4841
Andrea GsurCenter for Cancer Research, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Annika LindblomDepartment of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-7675-7569
Shuji OginoProgram in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3909-2323
Veronika VymetalkovaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-6870-6788
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7387-6845
Anna H WuUniversity of Southern California, Department of Population and Public Health Sciences, Los Angeles, California, USA.
Jeroen R HuyghePublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-6027-9806
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-5666-9318
Amanda I PhippsPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0009-0002-4864-8351
Claire E ThomasPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-9515-3277
Rish K PaiDepartment of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, USA.ORCID 0000-0002-2692-221X
Robert C GrantDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Daniel D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.ORCID 0000-0003-2225-6675
James YarmolinskyCancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, United Kingdom.
Marc J GunterNutrition and Metabolism Branch, International Agency for Research on Cancer, WHO, Lyon, France.ORCID 0000-0001-5472-6761
Jie ZhengDepartment of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID 0000-0002-6623-6839
Emma HazelwoodMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.ORCID 0000-0002-4888-6037
Emma E VincentMRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.ORCID 0000-0002-8917-7384

Funding

Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Transdisciplinary Studies of Genetic Variation in Colorectal CancerU19CA148107 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GRUBER, STEPHEN B · 2010 to 2014
$11.1M
MOLECULAR EPIDEMIOLOGY OF COLORECTAL CANCERR01CA081488 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRUBER, STEPHEN B · 1999 to 2008
$9.2M
Genomic Wide Association Study of Colorectal CancerU01CA122839 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CASEY, GRAHAM · 2006 to 2010
$7.3M
NCI NIH HHS R01 CA081488NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA167551NCI NIH HHS U19 CA148107NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008IWellcome Trust
6 · The paper itself

Abstract

Background: Recent research has identified a potential protective effect of higher numbers of circulating lymphocytes on colorectal cancer (CRC) development. However, the importance of different lymphocyte subtypes and activation states in CRC development and the biological pathways driving this relationship remain poorly understood and warrant further investigation. Specifically, CD4+ T cells - a highly dynamic lymphocyte subtype - undergo remodelling upon activation to induce the expression of genes critical for their effector function. Previous studies investigating their role in CRC risk have used bulk tissue, limiting our current understanding of the role of these cells to static, non-dynamic relationships only. Methods: Here, we combined two genetic epidemiological methods - Mendelian randomisation (MR) and genetic colocalisation - to evaluate evidence for causal relationships of gene expression on CRC risk across multiple CD4+ T cell subtypes and activation stage. Genetic proxies were obtained from single-cell transcriptomic data, allowing us to investigate the causal effect of expression of 1,805 genes across five CD4+ T cell activation states on CRC risk (78,473 cases; 107,143 controls). We repeated analyses stratified by CRC anatomical subsites and sex, and performed a sensitivity analysis to evaluate whether the observed effect estimates were likely to be CD4+ T cell-specific. Results: We identified six genes with evidence (FDR- Conclusions: Our study demonstrates the importance of capturing the dynamic nature of CD4+ T cells in understanding disease risk, and prioritises genes for further investigation in cancer prevention research.

Identifiers

PMID40321251
PMCPMC12047913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.